Vertex will acquire Alpine Immune Sciences, a Seattle-based biotech with a focus on protein-based immunotherapies, in a deal worth approximately $4.9 billion.
If approved, povetacicept would be the first therapy that targets the underlying cause of IgAN. The dual BAFF/APRIL antagonist is also being studied in renal indications and autoimmune cytopenias.
The Alpine deal solidifies Vertex's ambitions beyond CF, expanding the company's reach into other serious diseases with unmet need. In the kidney disease space, earlier this month, Vertex advanced its investigational small molecule inhibitor of APOL1, inaxaplin, into phase 3 trials in APOL1-mediated kidney diseaseAPOL1-mediated kidney disease.
According to Vertex, the Alpine transaction was unanimously approved by both the Vertex and Alpine boards and is anticipated to close later this quarter.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.